If you have been diagnosed with PCOS – or suspect you might have it – there is a landmark development you need to know about.
On May 12, 2026, one of the world’s most prestigious medical journals, The Lancet, announced that Polycystic Ovary Syndrome (PCOS) has been officially renamed Polyendocrine Metabolic Ovarian Syndrome – or PMOS.
This is not just a new label. It is a formal, evidence- backed acknowledgment that this condition has been misunderstood, underdiagnosed, and undermanaged for decades. And for the millions of women living with it, the name change signals a long-overdue revolution in care.
Why Was PCOS Is Now PMOS ?
The push to rename PCOS has been building for years. A 2012 NIH workshop first flagged that the original name was scientifically inaccurate – and the evidence only grew stronger from there.
The new name came out of a massive global consensus process led by the Monash Centre for Health Research and Implementation, alongside 56 academic, clinical, and patient organizations worldwide. Over 14,360 survey responses were collected from patients and clinicians across every world region.
The problems with the old name were clear:
- “Polycystic ovary” was never accurate. Those so-called “cysts” are not cysts at all. They are immature follicles – arrested in development due to hormone dysregulation. There is no primary ovarian pathology. The ovary is a victim of upstream disruption, not the cause of the problem.
- It reduced a complex, whole-body condition to a single organ.PCOS was consistently treated as a reproductive issue. Fertility Periods. The ovaries. But the true condition -now called PMOS – affects the brain, adrenal glands, pancreas, liver, heart, and metabolic system. Treating only the ovaries is like treating a symptom while ignoring the disease.
- It left millions undiagnosed and underserved. Up to 70% of individuals with PMOS remain undiagnosed. Patient dissatisfaction with information and care has been consistently documented – and the misleading name is part of why.
What Does PMOS Actually Mean?
The new name – Polyendocrine Metabolic Ovarian Syndrome – was chosen for scientific accuracy, cultural appropriateness, and stigma reduction. Each word carries weight.
POLYENDOCRINE: It Starts in the Brain, Not the Ovaries
The “poly” in PMOS is perhaps the most important shift. This condition involves multiple interacting endocrine systems:
- The hypothalamic-pituitary-ovarian (HPO) axis
- Adrenal androgen production
- The pancreatic insulin-signaling pathway
- Adipokine signaling from fat tissue
- Gut hormone interactions
In PMOS, the hypothalamus fires GnRH (gonadotropin-releasing hormone) pulses too frequently. This raises LH relative to FSH, which drives excess androgen production from the ovaries. The dysregulation begins in the brain – not the ovary.
This means looking only at the ovaries and running a testosterone test is no longer adequate care. A whole- system view is essential.
METABOLIC: The Urgent, Often-Missed Picture
This is where the name change carries the greatest clinical urgency.
Insulin resistance is present in up to 85% of people with PMOS – including 75% of lean women. This is not a weight issue. It is a hormonal and metabolic issue that exists across all body types. For years, I, like many doctors accepted that medications like metformin, which is used to treat diabetes, was a mainstay of treatment for this condition. But the question remained-why would that work if it is only an ovarian issue?
Hyperinsulinemia (excess insulin) drives a vicious cycle:
- Amplifies ovarian androgen production
- Suppresses SHBG (sex hormone-binding globulin)
- Promotes central fat redistribution
- Worsens every other axis of the condition
The downstream consequences are serious:
- Heart disease: A 2024 meta-analysis found women with PMOS have 2.5x higher odds of heart attack and 1.7x higher odds of stroke
- Liver disease: 43% prevalence of metabolic liver disease (MASLD) – three times the general population risk
- Sleep apnea: Affects an estimated 30-40% of women with PMOS, yet is rarely screened for
- Type 2 diabetes: A significantly elevated lifetime risk
Despite all of this, most women with PMOS are only screened for fertility concerns. The metabolic and cardiovascular picture is routinely missed.
OVARIAN: The Ovary Is the Victim, Not the Villain
The ovary remains part of the picture – but the narrative around it has fundamentally shifted.
Follicular arrest (those “cysts”) is a downstream consequence of hyperinsulinemia and hormone disruption. Elevated AMH – now included in adult diagnostic criteria – reflects the abnormal follicle pool, not a primary ovarian disorder.
The shift in language matters for patients too. Being told your ovaries are “polycystic” creates fear, shame, and confusion. Understanding that your ovaries are responding to a system-wide imbalance is both more accurate and more empowering.
What Should You do if You Have PMOS (Formerly PCOS)?
The new name comes with new expectations for care. Here is what comprehensive PMOS management should include:
Complete Cardiometabolic Screening – Every person with PMOS should receive:
- Fasting insulin and glucose with HOMA-IR calculation
- Full lipid panel
- Liver function tests
- Blood pressure assessment at every visit
- Sleep apnea screening (when appropriate)
- 2-hour glucose tolerance test for elevated HOMA-IR
Hormonal and Reproductive Assessment:
- Anti-Mullerian hormone (AMH) – now a standard diagnostic marker
- LH/FSH ratio
- Free and total testosterone
- DHEA-S and androstenedione
- Full thyroid panel (thyroid dysfunction is common in PMOS)
Lifestyle as Medicine:
The evidence for lifestyle intervention in PMOS is strong. Even modest weight loss (5-10%) in those with excess weight significantly improves insulin sensitivity, ovulatory function, and androgen levels. Targeted nutrition, movement, and stress management are first-line – not afterthoughts.
Long-Term Monitoring:
PMOS is a lifelong condition. It does not disappear after pregnancy or menopause. Cardiovascular, metabolic, and liver health require ongoing attention across the lifespan.
What Does This Mean for Fertility?
If you are trying to conceive and have PMOS, the picture is more nuanced – and more hopeful – than the old framing suggested.
Yes, anovulation (lack of ovulation) is common. But the underlying drivers – insulin resistance, androgen excess, hormonal dysregulation – are addressable. When those root causes are treated, ovulatory function often improves.
A landmark 2024 randomized controlled trial (the BAMBINI trial) found that bariatric surgery led to spontaneous ovulation in a significant proportion of women with PMOS who had not previously ovulated. While surgery is not the answer for everyone, it confirms that metabolic correction is the key to restoring fertility – not just fertility drugs.
Pregnancy outcomes can be impacted by PMOS, with higher rates of gestational diabetes, preterm birth, and preeclampsia. This makes preconception care and metabolic optimization before pregnancy more important than ever.
THE BOTTOM LINE
PCOS was not just poorly named. It was poorly understood – and that affected the care millions of women received.
PMOS changes that. It says clearly: this is a whole-body, polyendocrine, metabolic condition that requires a whole-body approach to care.
If you have been told you have PCOS – or if you have been struggling with symptoms that have gone unexplained – now is the time to ask for the full picture.
You deserve a provider who looks at your whole system. Not just your ovaries.
If you have questions about PCOS, PMOS, fertility or other hormonal issues, book a free discovery call with us.
Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment.
SOURCES:
- The Lancet – PMOS Global Consensus Renaming, May 2026
- Teede HJ et al. – 2023 International Evidence-Based Guideline for PCOS
- 2024 Systematic Review – Cardiovascular outcomes in PCOS/PMOS
- 2023 Meta-analysis – MASLD prevalence in PCOS
- BAMBINI Trial – Bariatric surgery and ovulation, The Lancet 2024